Brightpath Biotherapeutics received FDA IND clearance for BP-2202, enabling first-in-human dosing in relapsed or refractory multiple myeloma. The company’s plan calls for Phase 1 initiation later this year, marking a new regulatory step for an asset in a competitive hematology landscape. Recursion also disclosed clinical progress: IND clearance for REC-7735, its AI-designed PI3Kα H1047R inhibitor, for a Phase I/II study in patients with select PIK3CA H1047R-mutant solid tumors. The report positions the program for a clinic start in the second half of the year. These IND clearances show continued momentum for precision and AI-discovered targets—where entering early clinical trials can quickly reshape investor expectations around target tractability and early pharmacology.